Business Wire

MATW-PROJECT

28.11.2022 12:12:36 CET | Business Wire | Press release

Share
Ali Banat, Founder of Muslims Around The World, Receives TRT World Citizen Award in Recognition of His Lifetime Contributions to Society

The ‘Muslims Around the World Project’ (MATW-Project), a new-generation non-governmental organization building heritage with global impact, was founded by Ali Banat, who passed away from cancer at a young age. To acknowledge his contribution, TRT World Citizen Awards, an organization that honors people who contribute greatly to society, has granted Ali Banat its Lifetime Achievement Award. Mahmoud Ismail, Ali Banat's friend and the CEO of MATW-Project, received the award at the ceremony in Istanbul on November 25 from TRT World, the international English language broadcaster operated by Turkiye's national broadcaster TRT.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221128005245/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

CEO of MATW-Project Mahmoud Ismail and TRT Director General Prof. Zahid Sobacı (Photo: Business Wire)

Ali Banat was an Arab-Australian businessperson who owned a security and electrical company and died in 2018, following a struggle with cancer. Following his cancer diagnosis in October 2015, Ali Banat donated all his wealth to charity and founded MATW-Project.

Mahmoud Ismail expressed his thoughts about the award, saying, "We lost Ali Banat but his legacy lives on in what he did for the world and for charity. His MATW-Project, based in Australia, carries on its business with a strong presence in many countries worldwide, especially in Africa. We would like to thank TRT World for recognizing the contributions of MATW to the world and granting this award to our founder Ali Banat."

This year, the TRT World Citizen Awards held its award ceremonies for the third time. The ceremony was attended by many international people from different parts of society, such as politics, academia, arts, entertainment, humanitarian aid, and business.

This non-profit organization cherishes Ali Banat's legacy and contributes to positive change worldwide. With its 774,000 supporters on social media, the MATW-Project has built more than 950 water wells in Africa to make up for the water shortage, supported more than 1,000 orphan children and touched the lives of more than 3 million people.

The MATW-Project operates on a 100% donation basis, meaning that every donated amount is given to those in need, and provides humanitarian support in countries such as Bangladesh, Pakistan, Palestine, Yemen, Syria, and Afghanistan. It also provides shelter, access to water, education and guidance services in challenging living conditions.

Explaining that they want to maximize the impact of donations through a sustainable model, Ismail concluded his speech: "At the MATW-Project, we strive to build equitable and fair living conditions compatible with human dignity; inspired by our values of reliability, efficiency, sustainability, impact, and belief. I hope that this Lifetime Achievement Award from TRT World to our Founder Ali Banat will help further raise awareness of the MATW-Project's activities by reaching more people around the globe."

Visit us at https://matwproject.org

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221128005245/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release

Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi

Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme

Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release

Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release

On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-

Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release

Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye